JPMorgan analyst Jessica Fye raised the firm’s price target on Crinetics to $54 from $47 and keeps an Overweight rating on the shares. The analyst moved the price target to year-end 2025 from the end of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics files to sell common stock for holders, no amount given
- Crinetics files automatic mixed securities shelf
- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics price target raised to $74 from $55 at Oppenheimer